cas 851386-32-8|| where to buy 4-chloro-5,6-difluoronicotinic acid

Product Name:4-chloro-5,6-difluoronicotinic acid

IUPAC Name:4-chloro-5,6-difluoropyridine-3-carboxylic acid

Packing Unit	Available Stock	Price($)
CM132506-250mg	in stock	ǕŔƅ
CM132506-1g	in stock	șƅǺ
CM132506-5g	1-2 Weeks	Ǻƅƅ
CM132506-10g	3-4 Weeks	ǕƅǺǕ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 851386-32-8 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:851386-32-8; Molecular Formula:C6H2ClF2NO2; Melting Point:-; Smiles Code:O=C(O)C1=CN=C(F)C(F)=C1Cl; Density:

: Catalog Number:CM132506; Molecular Weight:193.53; Boiling Point:297.1°C at 760 mmHg; MDL No:MFCD09031172; Storage:Keep in inert atmosphere, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: IAG933; IAG933 is a potent, selective, and first-in-class inhibitor from Novartis that directly inhibits the protein-protein interaction (PPI) between YAP/TAZ and TEAD. By blocking this PPI, IAG933 interferes with oncogenic functions downstream of the Hippo signaling pathway, particularly in mesothelioma and other tumors with NF2 loss-of-function mutations or YAP/TAZ fusions. This inhibition reduces transcriptional activity and induces cell death in cancer cells, leading to significant tumor regressions in xenograft models. Additionally, combining IAG933 preclinically with other targeted therapies (i.e., RTK, KRAS-mutant selective, and MAPK inhibitors) shows promise for improving the efficacy and durability of treatment responses. IAG933 is currently being evaluated in a Ph. I trial (NCT04857372) for solid tumors with Hippo pathway alterations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.